ClinicalTrials.gg
RecruitingNCT07374848Updated Nov 18, 2026

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

A Phase 1 interventional study of ZL-6201 in Solid Tumors and Sarcomas, sponsored by Zai Lab (Shanghai) Co., Ltd.. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 18, 202610 sites added6 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 242 under way, 4 of them phase 3. Sarcoma · United States.

Planned enrollment
72nd of 800
180 · median 35
Started
2026
with 37 others
Phase 1
281 of 958
36 open now
Primary completion
2028-08
later than 172 of 240 live
Registered
932nd of 958
by date

Among the 958 studies in Sarcoma with a site in United States, this one is the 72nd largest by planned enrollment of the 800 interventional ones that give a count, is one of 38 that started in 2026, is one of 281 in phase 1, reaches primary completion later than 172 of the 240 other live ones, and was the 932nd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:

148 more — sign in →

All 153 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 958 studies in Sarcoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

Read the detailed description

An Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants with Sarcoma and Selected Solid Tumors

03

Conditions studied

  • Solid Tumors
  • Sarcomas

Browse trials for

Keywords

  • Sarcoma
  • Solid Tumors
  • Phase1
  • Antibody-Drug Conjugate (ADC)
  • Leucine-Rich Repeat-Containing protein 15 (LRRC15)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult men and women ≥18 years of age at the time of signing the ICF with an (ECOG) performance status of 0 or 1 and a > 3 months
  • Participants must have confirmed and documented diagnosis of locally advanced unresectable and/or sarcoma or a selected solid tumor
  • Participants must be willing to undergo a tumor prior to start of treatment or provide archived tumor tissue sample
  • Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting
  • Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic/ refractory setting
  • Participants must have at least one measurable target lesion as defined by v1.1
  • Adequate organ and marrow function as listed per protocol
  • Must be negative for , , and

Exclusion criteria

Exclusion Criteria:

  • Participants with another known that has required treatment within the last 2 years
  • Symptomatic central nervous system (CNS) , and/or those requiring therapy with or anticonvulsants to control associated symptoms
  • Participants with
  • Most recent systemic anti-cancer treatment or products/devices less than 3 weeks
  • Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate
  • Impaired cardiac function or cardiac disease within the last 3 months before administration of the first dose of the study treatment
  • Clinically significant pulmonary disease including , connective tissue, or inflammatory conditions
  • Pregnant or nursing (lactating) women
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    ZL-6201

    ZL-6201 as a single agent

    Drug: ZL-6201

Interventions

  • DrugZL-6201

    ZL-6201 as a single-agent

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities

    Number of subjects with dose limiting toxicities (DLTs) through dose escalation only.

    Time frame: 1 cycle of study treatment (each cycle is 21 days)

  2. Incidence of Treatment Emergent Adverse Events

    Number of subjects with treatment-emergent adverse effects through dose escalation and expansion.

    Time frame: 36 months

  3. Incidence of Serious adverse events

    Number of subjects with Serious Adverse Events through dose escalation and expansion.

    Time frame: 36 months

  4. Number of participants with clinical laboratory abnormalities

    Time frame: 36 months

  5. Number of participants with vital sign abnormalities

    Vitals will be measured in Riva Rocci (RR) in mmHG and Pulse in beats per minute

    Time frame: 36 months

  6. Number of participants with electrocardiogram (ECG) abnormalities

    ECG will be measured in ECG intervals (QT and QTc with Fridericia correction, and PR), QRS duration, and heart rate will be tested and analyzed.

    Time frame: 36 months

Secondary outcomes

  1. ORR per RECIST 1.1

    Objective Response Rate (ORR) is defined as the proportion of participants who have a best response of confirmed partial response (PR) or confirmed complete response (CR) to study treatment per RECIST v1.1 by investigator assessment through dose escalation and expansion.

    Time frame: 36 months

  2. Duration of Response per RECIST 1.1

    Duration of Response is defined as the time from the first assessment of CR or PR to the first assessment of progression disease (PD) by investigator per RECIST 1.1 or death due to any cause (whichever occurs first) through dose escalation and expansion.

    Time frame: 36 months

  3. PFS per RECIST 1.1

    Progression-Free Survival (PFS) is defined as the time from first dosing date to the first documented PD by investigator per RECIST 1.1 or death for any reasons (whichever occurs first) through dose escalation and expansion.

    Time frame: 36 months

  4. DCR per RECIST 1.1

    Disease Control Rate (DCR) is defined as the proportion of participants who have a best response of confirmed CR, confirmed PR, or SD per RECIST 1.1 by investigator assessment through dose escalation and expansion.

    Time frame: 36 months

  5. PK characteristics of ZL-6201 (ADC conjugate), total antibody

    Pharmacokinetics: Total Antibody of ZL-6201

    Time frame: 36 months

  6. PK characteristics of ZL-6201 (ADC conjugate), unconjugated payloads

    Pharmacokinetics: Unconjugated payloads of ZL-6201

    Time frame: 36 month

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2028, 29 months after the start.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 29, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Sep 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 6 sites removed
Show 10 added (7 United States, 3 China)
  • USC Norris Cancer Hospital · Los Angeles, United States
  • Yale Cancer Center · New Haven, United States
  • Florida Cancer Specialist · Sarasota, United States
  • Washington University in St. Louis · St Louis, United States
  • Memorial Sloan-Kettering Cancer Center · Long Island City, United States
  • NYU Langone Health · New York, United States
  • Virginia Cancer Specialists · Fairfax, United States
  • Peking University People's Hospital · Beijing, China
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • Shanghai Sixth People's Hospital · Shanghai, China
Show 6 removed
  • Zai Lab Site 02003 · Los Angeles, United States
  • Zai Lab Site 02030 · New Haven, United States
  • Zai Lab Site 02026 · Sarasota, United States
  • Zai Lab Site 02005 · St Louis, United States
  • Zai Lab Site 02002 · New York, United States
  • Zai Lab Site 02006 · Fairfax, United States
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    10 sites added, 6 sites removed
    Show 10 added (7 United States, 3 China)
    • USC Norris Cancer Hospital · Los Angeles, United States
    • Yale Cancer Center · New Haven, United States
    • Florida Cancer Specialist · Sarasota, United States
    • Washington University in St. Louis · St Louis, United States
    • Memorial Sloan-Kettering Cancer Center · Long Island City, United States
    • NYU Langone Health · New York, United States
    • Virginia Cancer Specialists · Fairfax, United States
    • Peking University People's Hospital · Beijing, China
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • Shanghai Sixth People's Hospital · Shanghai, China
    Show 6 removed
    • Zai Lab Site 02003 · Los Angeles, United States
    • Zai Lab Site 02030 · New Haven, United States
    • Zai Lab Site 02026 · Sarasota, United States
    • Zai Lab Site 02005 · St Louis, United States
    • Zai Lab Site 02002 · New York, United States
    • Zai Lab Site 02006 · Fairfax, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07374848
Collaborators
Zai Lab (US) LLC
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Mar 2, 2026
Primary completion
Aug 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

ZL-6201-001 Study Team
Contact
ZL-6201-001@zailaboratory.com
650.360.1601

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion